Your browser is out of date

With an updated browser, you will have a better Medtronic website experience. Update my browser now.

×

Skip to main content

Transcatheter aortic valve implantation (TAVI)

Evolut™ TAVI implant procedure

with the cusp overlap technique

Delivering on ease of use through a more predictable and streamlined procedural experience.

Alert Indications, Safety, and Warnings
Evolut FX transcatheter aortic valve being deployed using the Evolut TAVR/TAVI implant procedure

Precision

Facilitate implant depth accuracy
The cusp overlap view isolates the noncoronary cusp and elongates the left ventricular outflow tract, providing a greater visual separation between the basal annular plane and the conduction system, and an accurate, patient-specific anatomical view to assess and achieve target implant depth.1

Control

Predictable valve deployment
Slow deployment starting from a supra-annular position allows the valve to descend to its target position, providing users with control over valve deployment and requiring minimal catheter manipulation, which minimizes the risk of interaction with the conduction system.

Optimize PRO second interim analysis1

The cusp overlap technique with an optimized care pathway continues to show dependable clinical outcomes.*

Accuracy when it matters most

  • Reproducible single-digit pacemaker rate: 9.8% PPI rate at 30 days
  • No ≥ moderate PVL at discharge
  • 1 day median discharge
  • No PPM in 91% of patients at discharge

Devices used: 91.5% Evolut™ PRO+/8.0% Evolut™ PRO.
* This is an interim analysis of 400 main cohort patients. At the conclusion of the study, more than 650 patients will have been evaluated.

Real-world accuracy

Accurate depth assessment at the NCC, facilitated with the cusp overlap technique, has resulted in single-digit pacemaker rates in several single-center and multicenter clinical studies.

Single-digit new 30-day permanent pacemaker implantation rates

Bar chart highlighting 30-day pacemaker implant rates for multiple studies following TAVR or TAVI, depending on region or country

Excludes patients with baseline implantable cardioverter defibrillator or pacemaker.
†Discharge rates.

TAVI risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.

Explore the Evolut TAVI implant procedure on Medtronic Academy.

Find training modules, live cases, webinars, and more at your fingertips.

Watch the technique

Related pages

Explore our other procedural guidance and outcomes you can expect from the Evolut platform.
Evolut transcatheter aortic valve with catheter accessing the coronary

Post-TAVI coronary access

Review the guidance
Evolut 29 mm transcatheter aortic valve within a circular outline

Durability starts with design

Explore our design
Top-down view of the Evolut transcatheter aortic valve within a circular outline

Comprehensive clinical evidence

Explore the data

References

1

Grubb JK, Gada H, Mittal S, et al. Clinical Impact of Standardized TAVR Technique and Care Pathway: Insights from the Optimize PRO Study. JACC Cardiovasc Interv. March 13, 2023;16(5):558–570.

2

Gada H. TAVR in Low Risk Patients. Presented at TVT 2019.

3

Gada H, et al. Reduction of Rates of Permanent Pacemaker Implantation With 34-MM Evolut™ R Using Cusp Overlap Technique. Presented at TCT Connect 2020.

4

Gada H, et al. Reproducibility of Cusp Overlap Technique to Reduce Permanent Pacemaker Implantation With Evolut™: The Latin American Experience. Presented at TCT Connect 2020.

5

Pisaniello AD, Makki HBE, Jahangeer S, Daniels MJ, Hasan R, Fraser DGW. Low Rates of Permanent Pacing Are Observed Following Self-Expanding Transcatheter Aortic Valve Replacement Using an Annular Plane Projection for Deployment. Circ Cardiovascular Interv. January 2021;14(1):e009258.

6

Mendiz OA, Noč M, Fava CM, et al. Impact of Cusp-Overlap View for TAVR with Self-Expandable Valves on 30 Day Conduction Disturbances. J Interv Cardiol. April 28, 2021;2021:9991528.